Hong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hong Li has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Lu Xu
Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China
4 shared publicationsMing Chen
Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China
4 shared publicationsNan Li
Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China
4 shared publicationsShen Qu
Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China
4 shared publicationsLe Bu
Department of Endocrinology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China
3 shared publicationsLu Liu
Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China
3 shared publications
Latest Publications
- 1 September 2018
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 143, 239-244
Lower alpha fetoprotein and higher risk of hepatocellular carcinoma, study from the type 2 diabetes mellitus patients
- 1 September 2018
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 143, 239-244
Lower alpha fetoprotein and higher risk of hepatocellular carcinoma, study from the type 2 diabetes mellitus patients
- 1 July 2018
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 141, 80-87
Association of diabetes mellitus with prostate cancer grade and prostate-specific antigen in Chinese biopsy population
- 1 July 2018
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 141, 80-87
Association of diabetes mellitus with prostate cancer grade and prostate-specific antigen in Chinese biopsy population
- Open Access
- 17 January 2018
- Published by Springer Nature in Pediatric Research
- Vol. 83 (5) , 954-960
Effect of recombinant human growth hormone therapy on blood lipid and carotid intima-media thickness in children with growth hormone deficiency
Background: Reports on the association between growth hormone deficiency (GHD) and cardiovascular risk factors in children are limited. We aim to investigate the effect of different doses of recombinant human growth hormone (rhGH) therapy on blood lipid and carotid intima-media thickness (cIMT) in Chinese GHD children. Methods: Ninety children, including sixty isolated GHD children and thirty healthy children, were enrolled. GHD children were randomly divided into two groups (A and B) according to the rhGH dose given: group A received 0.23 mg/kg/week and group B received 0.35 mg/kg/week for 12 months. The TC, TG, LDL-C, HDL-C, and cIMT at baseline and after treatment were measured. Results: The height, weight, and height velocity improved significantly over 12 months of rhGH therapy in all GHD children. At baseline, GHD children in both the treatment groups showed significantly higher total cholesterol (TC), triglyceride (TG), low-density lipoprotein-cholesterol (LDL-C), cIMT, and lower high-density lipoprotein-cholesterol (HDL-C) than healthy children (all P≤0.033). After the 12-month rhGH therapy, a significant decrease in the TC, TG, LDL-C, and cIMT, as well as a significant increase in the HDL-C (P≤0.046), was observed in the GHD children, with change in the group B being even more marked. Conclusions: The RhGH replacement therapy in GHD children can improve both the blood lipid profile and carotid intima-media thickness, with higher-dose rhGH therapy showing superior effects.
- 17 January 2018
- Published by Springer Nature in Pediatric Research
- Vol. 83 (5) , 954-960
Open AccessEffect of recombinant human growth hormone therapy on blood lipid and carotid intima-media thickness in children with growth hormone deficiency
Background: Reports on the association between growth hormone deficiency (GHD) and cardiovascular risk factors in children are limited. We aim to investigate the effect of different doses of recombinant human growth hormone (rhGH) therapy on blood lipid and carotid intima-media thickness (cIMT) in Chinese GHD children. Methods: Ninety children, including sixty isolated GHD children and thirty healthy children, were enrolled. GHD children were randomly divided into two groups (A and B) according to the rhGH dose given: group A received 0.23 mg/kg/week and group B received 0.35 mg/kg/week for 12 months. The TC, TG, LDL-C, HDL-C, and cIMT at baseline and after treatment were measured. Results: The height, weight, and height velocity improved significantly over 12 months of rhGH therapy in all GHD children. At baseline, GHD children in both the treatment groups showed significantly higher total cholesterol (TC), triglyceride (TG), low-density lipoprotein-cholesterol (LDL-C), cIMT, and lower high-density lipoprotein-cholesterol (HDL-C) than healthy children (all P≤0.033). After the 12-month rhGH therapy, a significant decrease in the TC, TG, LDL-C, and cIMT, as well as a significant increase in the HDL-C (P≤0.046), was observed in the GHD children, with change in the group B being even more marked. Conclusions: The RhGH replacement therapy in GHD children can improve both the blood lipid profile and carotid intima-media thickness, with higher-dose rhGH therapy showing superior effects.
- Open Access
- 1 January 2018
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 15 (3) , 228-237
Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study
Aims: Whether pioglitazone (PIO), a peroxisome proliferator-activated receptor-gamma agonist, increases the risk of developing bladder cancer has been debated for several years. The aim of this study was to investigate the in vitro effects of PIO on normal urothelial transitional epithelium (NUTE) cells and bladder cancer (J82) cells to further evaluate the risk.
- 1 January 2018
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 15 (3) , 228-237
Open AccessPioglitazone Use and Risk of Bladder Cancer: an In Vitro Study
Aims: Whether pioglitazone (PIO), a peroxisome proliferator-activated receptor-gamma agonist, increases the risk of developing bladder cancer has been debated for several years. The aim of this study was to investigate the in vitro effects of PIO on normal urothelial transitional epithelium (NUTE) cells and bladder cancer (J82) cells to further evaluate the risk.
- Open Access
- 1 March 2015
- Published by Bioscientifica in Endocrine Connections
- Vol. 4 (1) , 58-64
Association between alendronate and atypical femur fractures: a meta-analysis
Alendronate (ALN) is a commonly used drug for the treatment of osteoporosis. Atypical femur fractures (AFFs) have been associated with long-term use of ALN and have recently become the subject of considerable attention as ALN use increases. This meta-analysis aimed to determine the relationship between ALN and AFF. The Embase, PubMed, and Cochrane library databases were searched for relevant studies published before November 6, 2014. Studies clearly reporting the relationship between ALN and AFF were selected for our analysis. From these results, the relationship between ALN and AFF was analyzed. Weighted mean differences were calculated using a random-effects model. Five studies were included in this meta-analysis. The results revealed that the use of ALN will not increase the risk of AFF in short term (P>0.05), but there will be a risk of AFF (P5 years) use of ALN. These findings indicate that long-term use of ALN is a risk factor for AFF and that more attention should be paid to the clinical applications of ALN.
- 1 March 2015
- Published by Bioscientifica in Endocrine Connections
- Vol. 4 (1) , 58-64
Open AccessAssociation between alendronate and atypical femur fractures: a meta-analysis
Alendronate (ALN) is a commonly used drug for the treatment of osteoporosis. Atypical femur fractures (AFFs) have been associated with long-term use of ALN and have recently become the subject of considerable attention as ALN use increases. This meta-analysis aimed to determine the relationship between ALN and AFF. The Embase, PubMed, and Cochrane library databases were searched for relevant studies published before November 6, 2014. Studies clearly reporting the relationship between ALN and AFF were selected for our analysis. From these results, the relationship between ALN and AFF was analyzed. Weighted mean differences were calculated using a random-effects model. Five studies were included in this meta-analysis. The results revealed that the use of ALN will not increase the risk of AFF in short term (P>0.05), but there will be a risk of AFF (P5 years) use of ALN. These findings indicate that long-term use of ALN is a risk factor for AFF and that more attention should be paid to the clinical applications of ALN.
- 4 December 2014
- Published by Springer Nature in Medical Oncology
- Vol. 32 (1) , 422
Metabolic syndrome in hematologic malignancies survivors: a meta-analysis
The results from the published studies on whether the risk of metabolic syndrome is high among hematologic malignancies survivors are conflicting. The aims of this study are to conduct a systematic search and assess the literature to determine the available evidence on the association between metabolic syndrome and hematologic malignancies. Two reviewers independently conducted a systemic search to identify the available evidence from PubMed, EMBASE, and Cochrane database from database inception to June 4, 2014. The articles were limited to human studies and published in English. A combined analysis was performed, followed by a subgroup analyses stratified by the type of hematologic malignancies, hematologic malignancies treatment modality, criteria of metabolic syndrome, and individual components of metabolic syndrome. Publication bias was assessed using the Begg and Egger’s tests and visual inspection of funnel plot. All analysis was performed using Stata SE version 10.0 software package. Seven cross-sectional studies with a total of 3,550 participants were included in the analysis. Compared with the healthy control groups, the hematologic malignancies survivors were at an increased risk of metabolic syndrome, in the random-effect meta-analysis of all seven cross-sectional studies (OR 2.03; 95 % confidence interval (CI) 1.23–3.35; I 2 = 43.9 %). In the subgroup meta-analysis by cancer treatment modality, a significant positive association was observed for hematopoietic stem cell transplantation (OR 2.40; 95 % CI 1.71–3.35). However, no significant positive association was observed for other major cancer treatment modality, including chemotherapy and radiation therapy. Further subgroup analysis by individual metabolic syndrome components showed that the risk of high blood pressure among hematologic malignancies survivors (OR 1.67; 95 % CI 1.10–2.53) was found to be higher compared with central obesity (OR 1.43; 95 % CI 1.02–2.01), whereas no significant association between hematologic malignancies survivors and other individual components including high glucose levels, high triglyceride levels, and low HDL cholesterol levels was observed. Funnel plot inspection and Begg and Egger’s tests showed no evidence of publication bias for combined analysis. Our meta-analysis of studies showed that hematologic malignancies survivors were at an increased risk of metabolic syndrome.
- 4 December 2014
- Published by Springer Nature in Medical Oncology
- Vol. 32 (1) , 422
Metabolic syndrome in hematologic malignancies survivors: a meta-analysis
The results from the published studies on whether the risk of metabolic syndrome is high among hematologic malignancies survivors are conflicting. The aims of this study are to conduct a systematic search and assess the literature to determine the available evidence on the association between metabolic syndrome and hematologic malignancies. Two reviewers independently conducted a systemic search to identify the available evidence from PubMed, EMBASE, and Cochrane database from database inception to June 4, 2014. The articles were limited to human studies and published in English. A combined analysis was performed, followed by a subgroup analyses stratified by the type of hematologic malignancies, hematologic malignancies treatment modality, criteria of metabolic syndrome, and individual components of metabolic syndrome. Publication bias was assessed using the Begg and Egger’s tests and visual inspection of funnel plot. All analysis was performed using Stata SE version 10.0 software package. Seven cross-sectional studies with a total of 3,550 participants were included in the analysis. Compared with the healthy control groups, the hematologic malignancies survivors were at an increased risk of metabolic syndrome, in the random-effect meta-analysis of all seven cross-sectional studies (OR 2.03; 95 % confidence interval (CI) 1.23–3.35; I 2 = 43.9 %). In the subgroup meta-analysis by cancer treatment modality, a significant positive association was observed for hematopoietic stem cell transplantation (OR 2.40; 95 % CI 1.71–3.35). However, no significant positive association was observed for other major cancer treatment modality, including chemotherapy and radiation therapy. Further subgroup analysis by individual metabolic syndrome components showed that the risk of high blood pressure among hematologic malignancies survivors (OR 1.67; 95 % CI 1.10–2.53) was found to be higher compared with central obesity (OR 1.43; 95 % CI 1.02–2.01), whereas no significant association between hematologic malignancies survivors and other individual components including high glucose levels, high triglyceride levels, and low HDL cholesterol levels was observed. Funnel plot inspection and Begg and Egger’s tests showed no evidence of publication bias for combined analysis. Our meta-analysis of studies showed that hematologic malignancies survivors were at an increased risk of metabolic syndrome.